Global Gilead Sciences’ Jacopo Andreose PhD is a 20+ year pharma veteran and is today responsible for setting company strategy, planning and execution for over 150 countries across Asia, Russia/CIS, Latin and Central America, the Middle East, and Africa. In an exclusive conversation, Andreose outlines how Gilead was able to roll…
China Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential tool to shifting away from the country’s zero-COVID policy – is under threat from new mutations of the virus. Other…
Europe When the COVID-19 pandemic struck in early 2020, Europe’s reliance on active pharmaceutical ingredient (API) and generic medicine suppliers outside of the continent was laid bare. In the face of crisis, countries like India and China understandably looked first to safeguard their own populations which, combined with supply chain strains…
China As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market include Chinese firms’ deals to manufacture generic versions of Pfizer’s COVID antiviral, Kintor’s 229 percent share price leap after positive…
Global UNICEF is forecasting that between 16.8 billion and 20.9 billion COVID-19 vaccine doses will be produced in 2022. The Economist Intelligence Unit highlights the drivers of this incredible demand as the fact that booster shots will be needed to counter new variants; the increased number of countries requesting the Pfizer…
India The latest healthcare and pharma news from India, including the opening up of COVID-19 vaccine booster shots to all adults; the lowering of vaccine prices; and the licences granted to 19 Indian pharmaceutical firms for the generic version of Pfizer’s oral antiviral COVID-19 pill. COVID-19 vaccine booster shots now…
Global In 2022 global healthcare will continue to feel the effects of the pandemic and although COVID-19 has become less virulent, with the global death rate down to 0.4 percent from an initial peak of about three percent, new variants are still set to emerge this year. At the Economist Intelligence…
China Bridge Consulting’s Zoe Leung examines the journeys of Chinese-developed COVID-19 vaccines outside of China’s borders, drawing on a number of examples, from Sinopharm’s work on boosting vaccine supply in the UAE to Sinovac’s Egyptian and Chilean partnerships, CanSino’s steady progress in Pakistan and Mexico, and Zhifei Longcom’s Uzbek success.* …
Global The top COVID-19 Vaccines by revenue in 2021 and sales projections for 2022 based on Airfinity’s COVID-19 Vaccine Market Revenue Forecast 2022. Pfizer/BioNTech’s vaccine stands to make USD 42.69 billion in 2022, while Moderna’s product has projected sales of USD 25.71 billion. Projected USD 3.97 billion sales for Russia’s Sputnik…
China Despite rapidly developing and rolling out two vaccines against COVID-19 – from domestic firms Sinopharm and Sinovac – China is yet to approve a vaccine that uses mRNA technology, either from a domestic firm or one of the two international products (Pfizer/BioNTech and Moderna) currently approved elsewhere. As the…
China The latest news from Chinese healthcare and pharma including Western pharmacos’ moves to license therapies from Chinese partners to sell globally, the seismic impact of new COVID lockdown restrictions in major Chinese cities, and the Chinese firms at risk of being delisted in the US if they do not hand…
Spain HIPRA is a world-leading animal health company that has launched a record 22 animal vaccines in the last 10 years. During the COVID-19 pandemic, the European company decided to jump into human health with its own vaccine candidate, currently in phase III trials. Carles Fàbrega, managing director of HIPRA’s new…
See our Cookie Privacy Policy Here
